About this Research Topic
Respiratory infectious diseases are among the leading causes of morbidity and mortality worldwide, posing unprecedented threats to global public health, and economic and social development, especially throughout the COVID-19 pandemic. To cope with this plight, various strategies for the prevention and treatment of respiratory infectious diseases have been developed. Among these, immunity regulation strategies that utilize our immune system display impressive prophylactic and therapeutic promise, including vaccination and immunotherapy.
Bioengineered nanomedicine has been considered a superior platform to regulate host immunity for efficient prevention and treatment of human respiratory infectious diseases. Nanomedicine has improved the pharmacokinetic properties and therapeutic outcomes of traditional drugs with their controllable drug loading capacity, adjustable size distribution, various surface modification, practical targeting ability, etc. Recently, nanomedicine has been widely exploited in nanovaccines and immunotherapy for respiratory infectious diseases. Among them, two FDA-approved mRNA nanovaccines for COVID-19, mRNA-1273 and BNT162b, showed a huge advantage over the traditional vaccines. These cutting-edge studies of nanomedicine will provide important information for the fight against important human respiratory infectious diseases.
This Research Topic aims to advance the knowledge of the nanovaccines and nanotherapeutics against important human respiratory infectious diseases. We welcome submissions dealing with the following themes, including but not limited to:
•Establishment of novel nanotechnology for the design and development of highly effective vaccines and therapeutics against respiratory infectious diseases.
•Cutting-edge development of nanomedicine with immunity regulation for preventing and treating respiratory infectious diseases.
•Mechanisms of action of nanovaccines and immune-nanotherapeutics for respiratory infectious diseases.
•Design and develop new nanocarriers for the development of vaccines, including but not limited to the Lipid-based materials, Polymer-based carriers, Protein/peptide carriers, Inorganic carriers and others.
Bioengineered nanomedicine has been considered a superior platform to regulate host immunity for efficient prevention and treatment of human respiratory infectious diseases. Nanomedicine has improved the pharmacokinetic properties and therapeutic outcomes of traditional drugs with their controllable drug loading capacity, adjustable size distribution, various surface modification, practical targeting ability, etc. Recently, nanomedicine has been widely exploited in nanovaccines and immunotherapy for respiratory infectious diseases. Among them, two FDA-approved mRNA nanovaccines for COVID-19, mRNA-1273 and BNT162b, showed a huge advantage over the traditional vaccines. These cutting-edge studies of nanomedicine will provide important information for the fight against important human respiratory infectious diseases.
This Research Topic aims to advance the knowledge of the nanovaccines and nanotherapeutics against important human respiratory infectious diseases. We welcome submissions dealing with the following themes, including but not limited to:
•Establishment of novel nanotechnology for the design and development of highly effective vaccines and therapeutics against respiratory infectious diseases.
•Cutting-edge development of nanomedicine with immunity regulation for preventing and treating respiratory infectious diseases.
•Mechanisms of action of nanovaccines and immune-nanotherapeutics for respiratory infectious diseases.
•Design and develop new nanocarriers for the development of vaccines, including but not limited to the Lipid-based materials, Polymer-based carriers, Protein/peptide carriers, Inorganic carriers and others.
Keywords: nanovaccines, nanomedicine, human respiratory infectious diseases, mRNA vaccines
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
